John Hawkins, MD
Interventional Cardiology · Springfield, MONPI 1710076708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Abbott at 28.5% of the total. Reporting peaked in 2022 at $262 and has fallen 62.6% since, to $98 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.
Across 46 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$293
- Shockwave Medical, Inc$210
- Boston Scientific$141
- Biotronik Inc.$96
- Abiomed$88
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$65
- plus $135 from 5 others
What the payments were for
- Food & beverage$1,027100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $293 |
| Shockwave Medical, Inc | 5 | $210 |
| Boston Scientific | 10 | $141 |
| Biotronik Inc. | 2 | $96 |
| Abiomed | 4 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $65 |
| ZOLL Circulation Inc | 3 | $62 |
| Amgen | 2 | $32 |
| Boehringer Ingelheim | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Atricure, Inc. | 1 | $12 |
How this compares
$1,027 in reported general payments places this provider in the 5th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $37,955 |
| EntrestoSacubitril/Valsartan | 19 | $19,830 |
| Metoprolol Succinate | 44 | $451 |
| Potassium Chloride | 27 | $390 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 20 | $230 |
| Atorvastatin Calcium | 26 | $203 |
| Carvedilol | 56 | $199 |
| ClopidogrelClopidogrel Bisulfate | 26 | $182 |
| Losartan Potassium | 47 | $177 |
| Metoprolol Tartrate | 18 | $88 |
| Amlodipine Besylate | 24 | $82 |
| Lisinopril | 27 | $81 |
| Furosemide | 15 | $24 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Springfield
- Philipp WiesnerSpringfield$47K
- Amod AmritphaleSpringfield$19K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.